Previous 10 | Next 10 |
BioCryst Pharmaceuticals (BCRX) is up 14.7% in pre-market, as it received funding totaling $325M from Royalty Pharma (RPRX), and Athyrium Capital Management, LP, with $250M available at closing.The funding is to support the launch of ORLADEYO™ (berotralstat) in hereditary ang...
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX), BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 mil...
NEW YORK and RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX), Royalty Pharma plc (Nasdaq: RPRX) and Athyrium Capital Management, LP today announced transactions totaling $325 million in funding for BioCryst, with $250 million...
Royalty Pharma invests in biopharmaceutical royalty streams and has deployed $18bn of capital into the space since 1996 - ~50% of all deployed capital. Its portfolio of assets includes royalties from AbbVie's Imbruvica, Vertex' Cystic Fibrosis franchise and Biogen's Tysabri - all of w...
Royalty Pharma plc (RPRX) Q3 2020 Results Conference Call November 11, 2020 08:00 AM ET Company Participants George Grofik - SVP, Head, IR and Communications Pablo Legorreta - Founder and CEO Jim Reddoch - EVP and Head of Research & Investments Terry Coyne - EVP and CFO Chris Hite - Vice ...
Royalty Pharma (RPRX) Q3 results:Total income and other revenues of $538M grew 16% driven by the CF franchise and Imbruvica; beats consensus by $63.74M.Operating activities increased to $509M, compared with $436M during same period last year primarily due to higher royalty receipts....
The following slide deck was published by Royalty Pharma plc in conjunction with their 2020 Q3 earnings call. For further details see: Royalty Pharma plc 2020 Q3 - Results - Earnings Call Presentation
Double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts (1) Increased 2020 guidance: Adjusted Cash Receipts (1) expected to be $1,780 to $1,800 million $2.3 billion of new acquisitions announced in 2020, including $1.1 b...
Royalty Pharma (RPRX) inked an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals' cystic fibrosis treatments owned by the Cystic Fibrosis ((CF)) Foundation.Agreement includes an upfront payment of $575M and a potential milestone payment of $75M.Transaction is expect...
NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement to acquire the residual royalty interest in Vertex Pharmaceuticals, Inc.’s cystic fibrosis (CF) treatments owned by the Cystic Fibrosis Foundation. The agreement includes an upf...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...